1. United Kingdom Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Allergy Therapeutics plc

Allergy Therapeutics plc

0.06
EUR
0.00
(0.00%)
823.25MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.1
0.09
0.09
0.09
0.11
0.11
0.12
0.12
0.13
0.11
0.09
0.01
0.01
- -
Basic EPS, GAAP
- -
- -
- -
-0.02
- -
-0.01
0.01
0.01
- -
-0.02
-0.06
-0.01
-0.01
- -
Free Cash Flow per Basic Share
- -
- -
- -
-0.02
- -
-0.01
- -
0.02
0.01
-0.03
-0.05
-0.01
-0.01
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.04
0.04
0.06
0.05
0.05
0.04
0.06
0.07
0.07
0.06
0.01
- -
-0.01
- -
Tangible Book Value per Share
0.03
0.03
0.05
0.04
0.04
0.03
0.05
0.06
0.07
0.05
- -
- -
-0.01
- -
Basic Weighted Avg Shares
408
452
475
570
592
595
633
636
639
643
670
3,743
4,766
4,996
Sales/Revenue/Turnover
39
42
43
49
64
68
74
78
84
73
60
55
55
- -
Operating Margin (%)
1.7
2.88
1.68
-24.64
-2.96
-9.85
5.96
10.62
4.78
-16.83
-58.58
-61.63
-51.16
- -
Depreciation Expense
1
1
1
2
2
2
2
4
4
4
4
4
4
- -
Net Income, GAAP
1
1
- -
-13
-2
-8
3
7
3
-14
-43
-39
-40
- -
Effective Tax Rate (%)
- -
31.64
83.49
- -
- -
- -
19.24
12.55
21.08
- -
- -
- -
- -
- -
Profit Margin (%)
1.61
1.77
0.25
-26.95
-3.87
-11.02
4.7
9.03
3.42
-18.93
-72.28
-69.97
-72.91
- -
Working Capital
7
8
26
25
23
16
30
37
40
24
15
15
7
4
LT Debt
- -
- -
1
3
3
2
2
10
9
8
34
29
58
25
Total Equity
15
15
34
30
30
23
38
44
49
38
4
7
-28
4
Return on Invested Capital (%)
- -
5.35
0.46
- -
- -
- -
10.11
14.29
5.18
- -
- -
- -
- -
- -
Return on Capital (%)
- -
6.33
0.56
- -
- -
- -
10.98
15.63
5.66
- -
- -
- -
- -
- -
Return on Common Equity (%)
4.33
4.98
0.44
-40.35
-8.23
-28.43
11.44
17.35
6.25
-31.93
-205.72
-673.72
- -
- -

Capital Structure

GBP

•

in mil. unless spec.
Dec'25
Jun'25
Dec'26
ST Debt
2
2
2
LT Borrowings
37
53
20
LT Finance Leases
6
5
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4,766
4,766
6,141
Market Capitalization
334
293
718

Working Capital

GBP

•

in mil. unless spec.
Dec'25
Jun'25
Dec'26
Total Current Assets
42
35
36
Cash, Cash Equivalents & STI
22
13
10
Accounts Receivable, Net
9
3
11
Inventories
12
14
14
Total Current Liabilities
26
27
32
Payables & Accruals
- -
- -
- -
ST Debt
2
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-46.14%
-100.94%
-483.27%
Free Cash Flow
-72.43%
-66.2%
-11.28%
Net Income, GAAP
-1,255.38%
-86.04%
3.91%
Sales/Revenue/Turnover
3.33%
-6.33%
-0.28%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
55
2025
- -
- -
55
2026
- -
- -
- -

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.01
2025
- -
- -
-0.01
2026
- -
- -
- -

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Manuel Llobet
Full Time Employees
584
Sector
Health technology
Industry
Pharmaceuticals: other
Address
Dominion Way Worthing WS United Kingdom BN14 8SA
IPO Date
Oct 11, 2004
Website
allergytherapeutics.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Allergy Therapeutics plc stands as a commercial biotechnology enterprise dedicated to the research, development, and provision of treatments for allergic conditions. The company markets both injectable and sublingual allergen-specific immunotherapies, alongside diagnostic solutions. Its product range addresses common allergies, including those stemming from grasses, weeds, trees, and insect venoms, as well as advancing therapies for house dust mite and peanut allergies. Noteworthy offerings feature treatments like Pollinex Quattro, Oralvac, Venomil, ImmunoBON, and the developing VLP Peanut vaccine candidate. The firm distinguishes itself by focusing on ultra-short course and aluminum-free immunotherapies designed to enhance patient adherence and treatment efficacy. Its commercial operations span key European territories, including Central Europe, Southern Europe, and the United Kingdom, supplemented by international distribution channels. Recent developments include exploring a potential dual listing on the Hong Kong Stock Exchange, ongoing progress in the Grass MATA MPL immunotherapy program, including a Marketing Authorisation Application in Germany and a pediatric Phase III trial, and positive advancements in the VLP Peanut allergy vaccine trial. Allergy Therapeutics plc was established in 2004 and maintains its principal offices in Worthing, United Kingdom.

Company News

Company News APIChatGPT